SEHK:512Pharmaceuticals
Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After Positive DOORwaY90 Liver Cancer Trial Results
Grand Pharmaceutical Group (SEHK:512) just reported that its DOORwaY90 trial for SIR-Spheres Y-90 in unresectable hepatocellular carcinoma met its clinical endpoint, a key data point for investors watching its radiopharmaceutical pipeline.
See our latest analysis for Grand Pharmaceutical Group.
The DOORwaY90 success comes at a time when Grand Pharmaceutical Group’s short-term share price performance has been weak, with a 30-day share price return showing a decline of 5.35% and a 90-day share...